ERBB2 and cancer: Recently, the first randomized Phase III trial [Trastuzumab for GAstric cancer (ToGA)] showed that trastuzumab in combination with conventional chemotherapy is superior to conventional chemotherapy alone in HER2-positive advanced GC.12 Therefore, an accurate evaluation of HER2 status in GC has become increasingly important.